<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MILRINONE LACTATE</span><br/>(mil'ri-none)<br/><span class="topboxtradename">Primacor<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">inotropic agent</span>; <span class="classification">vasodilator</span><br/><b>Prototype: </b>Inamrinone<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg/mL, 200 mcg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Member of a class of inotropic/vasodilator agents. Positive inotropic action and vasodilator, with little chronotropic activity;
         mode of action and structure are different from digitalis and catecholamines as well as beta-adrenergic agonists. Inhibitory
         action against cyclic-AMP phosphodiesterase in cardiac and smooth vascular muscle. Increases cardiac contractility.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>In therapeutic dose, increases myocardial contractility. Therefore, increases cardiac output and decreases pulmonary wedge
         pressure and vascular resistance, without increasing myocardial oxygen demand or significantly increasing heart rate.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term management of CHF.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Short-term use to increase the cardiac index in patients with low cardiac output after surgery. To increase cardiac function
         prior to heart transplantation.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to milrinone.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Older adult; pregnancy (category C), lactation. Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Heart Failure</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Loading Dose</span> 50 mcg/kg IV over 10 min <span class="rdroute">IV Maintenance Dose</span> 0.3750.75 mcg/kg/min<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li> 						Note: Correct preexisting hypokalemia before administering milrinone. See manufacturer's information for dosage reduction in the
                     presence of renal impairment. 					
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Loading Dose:</span>  Give undiluted or dilute each 1 mg in 1 mL NS or 0.45% NaCl.  <span class="methodtype">IV Infusion:</span>  Dilute 20 mg of milrinone in D5W, NS, or 0.45% NaCl to yield: 100 mcg/mL with 180 mL diluent; 150 mcg/mL with 113 mL
                  diluent; 200 mcg/mL with 80 mL diluent.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Loading Dose:</span> Give 50 mcg/kg over 10 min.  <span class="methodtype">IV Infusion:</span> Give at a rate based on weight. Use a microdrip set and infusion pump.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Furosemide, procainamide.</b> <span class="incompattype"> Y-site:</span> <b>Furosemide, imipenem/cilastatin, procainamide.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store according to manufacturer's directions.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Increased ectopic activity, PVCs, ventricular tachycardia, ventricular fibrillation, supraventricular arrhythmias; possible
      increase in angina symptoms, hypotension. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Disopyramide</b> may cause excessive hypotension. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 2 min. <span class="typehead">Duration:</span> 2 h. <span class="typehead">Distribution:</span> 70% protein bound. <span class="typehead">Elimination:</span> 8085% excreted unchanged in urine within 24 h. Active renal tubular secretion is primary elimination pathway. <span class="typehead">Half-Life:</span> 1.72.7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiac status closely during and for several hours following infusion. Supraventricular and ventricular arrhythmias
            have occurred.
         </li>
<li>Monitor BP and promptly slow or stop infusion in presence of significant hypotension. Closely monitor those with recent aggressive
            diuretic therapy for decreasing blood pressure.
         </li>
<li>Monitor fluid and electrolyte status. Hypokalemia should be corrected whenever it occurs during administration.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately angina that occurs during infusion to physician.</li>
<li>Be aware that drug may cause a headache, which can be treated with analgesics.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>